Wednesday, September 16, 2009
WEDNESDAY, Sept. 16 (HealthDay News) -- Among breast cancer patients who receive adjunctive hormonal therapy with aromatase inhibitors, secondary causes of bone loss can be successfully treated, according to research presented this week at the annual meeting of the American Society for Bone and Mineral Research, held from Sept. 11 to 15 in Denver.
Pauline Camacho, M.D., of the Loyola University Medical Center in Chicago, and colleagues studied 81 patients who were referred for treatment or prevention of osteoporosis, including 51 with secondary causes of bone loss such as Vitamin D deficiency (65 percent), excessive calcium excretion in urine (16 percent), and an overactive parathyroid gland (13 percent). All patients were treated with bisphosphonates, and the group with secondary causes of bone loss received additional treatments such as prescription vitamin D supplements, diuretics, or medications to correct thyroid disorders.
After one year, the researchers found that appropriate treatment was associated with stable spine and femoral neck bone mineral density in the group with secondary causes of bone loss, and with increased bone mineral density in the group without secondary causes of bone loss.
"Our study shows that bone loss can be prevented in patients who use aromatase inhibitors for breast cancer when secondary causes of bone loss are corrected and bisphosphonates are appropriately utilized," the authors conclude.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.